Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The fluorouracil metabolic and resistance pathways encompass the biochemical network responsible for the activation, catabolism, and cellular response to the antimetabolite 5-fluorouracil (5-FU) [3, 13]. 5-FU is a pyrimidine analog that acts as a prodrug, requiring intracellular conversion by enzymes such as orotate phosphoribosyltransferase (UMPS) and thymidine phosphorylase (TP) into active metabolites, primarily fluorodeoxyuridine monophosphate (FdUMP) [4, 18]. FdUMP inhibits thymidylate synthase (TYMS), the rate-limiting enzyme in dTMP synthesis, thereby halting DNA replication and repair [12, 13]. Resistance to 5-FU is a major clinical challenge, often driven by the overexpression of TYMS, decreased activity of activating enzymes, or increased degradation by dihydropyrimidine dehydrogenase (DPD) [3, 9, 13]. These pathways are critical in the treatment of colorectal, breast, and aerodigestive cancers, where patient outcomes are heavily influenced by genetic variations in these metabolic components [13, 15]. Understanding these pathways allows for the identification of biomarkers like DPYD genotype to prevent severe toxicity [15]. Additionally, the pathway involves the incorporation of fluorinated nucleotides into RNA and DNA, further contributing to its cytotoxic profile [3, 12]. Therapeutic strategies often involve modulating these pathways, such as using leucovorin to stabilize the TYMS-FdUMP complex [13, 17].
5-FU is converted to active metabolites (FdUMP, FUTP, FdUTP) that exert cytotoxicity through three main mechanisms: (1) FdUMP binds to thymidylate synthase (TYMS) in a ternary complex with 5,10-methylenetetrahydrofolate, inhibiting dTMP synthesis and causing "thymineless" cell death; (2) FUTP is incorporated into RNA, disrupting processing and translation; and (3) FdUTP is incorporated into DNA, leading to strand breaks and apoptosis [3, 12, 13, 18].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fluorouracil metabolic and resistance pathways (5-FU pathway).